Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P ABOULKER

Showing results (121-130 of 134) with videos related to

Pageof 14
Sort By:
The New England Journal of Medicine|October 29, 1998
A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study TeamG Pialoux, F Raffi, F Brun-Vezinet, et al.
AIDS (London, England)|February 1, 1997
A prospective study of criteria for the diagnosis of toxoplasmic encephalitis in 186 AIDS patients. The BIOTOXO Study GroupF Raffi, J P Aboulker, C Michelet, et al.
Clinical and Experimental Immunology|November 13, 2001
CD4 T cell recovery is slower in patients experiencing viral load rebounds during HAARTD Scott-Algara, J P Aboulker, C Durier, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 29, 2000
Effect of a 14-day course of foscarnet on cytomegalovirus (CMV) blood markers in a randomized study of human immunodeficiency virus-infected patients with persistent CMV viremia. Agence National de Recherche du SIDA 023 Study GroupD Salmon-Céron, A M Fillet, J P Aboulker, et al.
HIV Medicine|March 16, 2012
Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replicationC Delaugerre, J Braun, I Charreau, et al.
AIDS (London, England)|June 10, 1998
Discrepant responses to triple combination antiretroviral therapy in advanced HIV diseaseC Piketty, P Castiel, L Belec, et al.
AIDS (London, England)|April 13, 2004
Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcomeJ-P Aboulker, A Babiker, M L Chaix, et al.
JAMA|January 14, 2000
Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team)D Descamps, P Flandre, V Calvez, et al.
Gut|February 22, 2014
Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADNH Fontaine, S Kahi, C Chazallon, et al.
Lancet (London, England)|July 25, 2006
Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial, P Yeni, D A Cooper, et al.
Pageof 14

Showing results (121-130 of 134) with videos related to

Sort By:
Pageof 14
The New England Journal of Medicine|October 29, 1998
A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study TeamG Pialoux, F Raffi, F Brun-Vezinet, et al.
AIDS (London, England)|February 1, 1997
A prospective study of criteria for the diagnosis of toxoplasmic encephalitis in 186 AIDS patients. The BIOTOXO Study GroupF Raffi, J P Aboulker, C Michelet, et al.
Clinical and Experimental Immunology|November 13, 2001
CD4 T cell recovery is slower in patients experiencing viral load rebounds during HAARTD Scott-Algara, J P Aboulker, C Durier, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 29, 2000
Effect of a 14-day course of foscarnet on cytomegalovirus (CMV) blood markers in a randomized study of human immunodeficiency virus-infected patients with persistent CMV viremia. Agence National de Recherche du SIDA 023 Study GroupD Salmon-Céron, A M Fillet, J P Aboulker, et al.
HIV Medicine|March 16, 2012
Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replicationC Delaugerre, J Braun, I Charreau, et al.
AIDS (London, England)|June 10, 1998
Discrepant responses to triple combination antiretroviral therapy in advanced HIV diseaseC Piketty, P Castiel, L Belec, et al.
AIDS (London, England)|April 13, 2004
Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcomeJ-P Aboulker, A Babiker, M L Chaix, et al.
JAMA|January 14, 2000
Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team)D Descamps, P Flandre, V Calvez, et al.
Gut|February 22, 2014
Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADNH Fontaine, S Kahi, C Chazallon, et al.
Lancet (London, England)|July 25, 2006
Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial, P Yeni, D A Cooper, et al.
Pageof 14